Ursprung des Netzwerks ersten Grades von Gary D Rakers
Einheit | Art der Einheit | Industrie | |
---|---|---|---|
Public Company | Biotechnology | 13 |
Unternehmensgrafik - zweiten Grades
Beziehungen zu mehreren Unternehmen
Unternehmensverbindungen über das persönliche Netzwerk von Gary D Rakers
Unternehmen | Sektor | Verknüpfte Personen | Hauptposition |
---|---|---|---|
Euroventures Benelux I BV
Euroventures Benelux I BV Investment ManagersFinance Euroventures Benelux I BV invests in life science companies located in the BeNeLux. The fund targets companies operating in the fields of drug development, therapeutics, diagnostics, technologies, medical devices, agriculture, clean technology, food, nutrition, and biofuels. It provides financing at all stages of a company's development from seed stage to pre-IPO capital requirements. It invests in both private and public companies. | Investment Managers | Corporate Officer/Principal | |
NPS PHARMACEUTICALS, INC. | Pharmaceuticals: Major | Corporate Officer/Principal Compliance Officer | |
QIAGEN N.V. | Medical Specialties | Director/Board Member | |
Advent Venture Partners LLP
Advent Venture Partners LLP Investment ManagersFinance Advent Venture Partners LLP (AVP) is a private equity/venture capital firm founded in 1981 by David James Scott Cooksey. The firm is headquartered in London, United Kingdom. | Investment Managers | Private Equity Investor Private Equity Investor | |
RADIUS HEALTH, INC. | Biotechnology | Chief Executive Officer Corporate Officer/Principal Corporate Officer/Principal | |
AURA BIOSCIENCES, INC. | Biotechnology | Director/Board Member Chairman | |
Artax Biopharma, Inc.
Artax Biopharma, Inc. Medical SpecialtiesHealth Technology Artax Biopharma, Inc. operates as a clinical-stage biopharmaceutical company. It engages in the development of new therapies for autoimmune and inflammatory diseases. The firm develops drugs targeting the interaction between T-cell Receptors (TCR) and Nck, a cytoplasmic adapter protein which plays a role in T-cell activation. The company was founded by Dami? Carulla Tormo in 2013 and is headquartered in Cambridge, MA. | Medical Specialties | Director of Finance/CFO Director/Board Member Director/Board Member | |
Zikani Therapeutics, Inc.
Zikani Therapeutics, Inc. Drugstore ChainsRetail Trade Zikani Therapeutics, Inc. is a preclinical-stage company developing and commercializing novel therapeutics. The company was founded by Lawrence G. Miller and Andrew G. Myers in 2014 and is headquartered in Watertown, MA. | Drugstore Chains | Director of Finance/CFO Director/Board Member Chairman Chief Executive Officer Chief Tech/Sci/R&D Officer | |
LSP Management Group BV
LSP Management Group BV Investment ManagersFinance LSP Management Group BV (LSP) is an independent European venture capital firm which was founded by Martijn Kleijwegt, Frits van der Have and Tom Schwarz in 1998. Headquartered in Amsterdam, the firm provides financing to early- to mid-stage life science companies. | Investment Managers | Founder | |
Massachusetts Institute of Technology | College/University | Doctorate Degree | |
Cornell University
Cornell University Other Consumer ServicesConsumer Services Cornell University is an educational institution that offers undergraduate and post graduate programs. It was founded in 1865 and is based in Ithaca, NY. | College/University | Masters Business Admin Masters Business Admin | |
University of Amsterdam | College/University | Undergraduate Degree | |
Intrexon ActoBiotics NV
Intrexon ActoBiotics NV BiotechnologyHealth Technology Intrexon ActoBiotics NV manufactures biopharmaceutical products. It focuses on the development and commercialization of a new generation of biological drugs. The company represents a novel concept for oral administration of therapeutic proteins, and is designed to be safer and more effective than injectable biopharmaceuticals. Intrexon Actobioticswas founded by Mark Vaeck, Emil Pot and Bernard Coulie in June 2006 and is headquartered in Zwijnaarde, Belgium. | Biotechnology | Director/Board Member | |
Euroventures Ukraine Fund II LP
Euroventures Ukraine Fund II LP Investment ManagersFinance EuroVentures Ukraine Fund II LP provides development and expansion capital to medium-sized Ukrainian companies. It acquires majority or significant minority interests. The fund targets the consumer services sector. | Investment Managers | Corporate Officer/Principal | |
Ploughshare Innovations Ltd.
Ploughshare Innovations Ltd. Miscellaneous Commercial ServicesCommercial Services Ploughshare Innovations Ltd. provides technology development and transfer services for the United Kingdom ministry of defense. The firm offers technologies to the life science, defence, cyber, biometrics, detection, diagnostics and electronics industries. The company was founded on March 22, 2002 and is headquartered in Stockbridge, the United Kingdom. | Miscellaneous Commercial Services | Director/Board Member | |
Natil Technologies Ltd.
Natil Technologies Ltd. Information Technology ServicesTechnology Services Natil Technologies Ltd. provides SAP technology and solutions. It focuses on outsourcing and offshore, systems integration & application development, software and consulting, and QA & training. The company was founded in 1999 and is headquartered in Tel Aviv, Israel. | Information Technology Services | Director/Board Member | |
AM-Pharma BV
AM-Pharma BV BiotechnologyHealth Technology AM-Pharma BV operates as a biopharmaceutical company. It engages in the development of proprietary recombinant human Alkaline Phosphatase. The firm’s products include Acute Kidney Injury, Inflammatory Bowel Diseases and Hypophosphatasia. The company was founded in 2001 and is headquartered in Bunnik, the Netherlands. | Biotechnology | Director/Board Member | |
The European Venture Capital Association | Director/Board Member | ||
EyeSense AG
EyeSense AG Medical SpecialtiesHealth Technology EyeSense AG develops novel continuous blood glucose monitoring systems for diabetes patients. The firm's continuous glucose monitoring (CGM) gives a sense of security to diabetic patients. The company was founded by Achim Müller in 2006 and is headquartered in Basel, Switzerland. | Medical Specialties | Director/Board Member | |
Advent Life Sciences LLP
Advent Life Sciences LLP BiotechnologyHealth Technology Part of Advent Venture Partners LLP, Advent Life Sciences LLP is a venture capital firm for visionary innovators. The company is based in London, UK. Advent Life Sciences has achieved its first discovery milestone in collaboration with Bristol Myers Squibb, and is focused on the journey from innovative science to an approved medicine or product. The British company has a history of delivering value and is one of the leading venture capital firms in the industry. | Biotechnology | Corporate Officer/Principal Corporate Officer/Principal | |
Eloxx Pharmaceuticals Ltd.
Eloxx Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Eloxx Pharmaceuticals Ltd. provides biopharmaceutical research and development services. The firm specializes in the discovery, development, and commercialization of drug compounds for the treatment of genetic diseases. It focuses on the treatment of diseases caused by nonsense mutations, including Cystic fibrosis, Duchene Muscular Dystrophy, Usher syndrome, Ataxia-telangiectasia, Beta thalassemia, and Tay-Sachs Hurler syndrome. Its focus areas encompass clinical drug development and target drugs discovery programs. The company was founded by Silvia Noiman and Shmuel Tuvia in 2013 and is headquartered in Herzliya, Israel. | Pharmaceuticals: Major | Director/Board Member Chief Executive Officer | |
PHARVARIS N.V. | Pharmaceuticals: Major | Director/Board Member | |
Arrakis Therapeutics, Inc.
Arrakis Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Arrakis Therapeutics, Inc. operates as a biopharmaceutical company. It develops rna-targeted small molecule medicines focused on neurologic, cancer, and rare genetic diseases. The company was founded by Russell C. Petter, Alan E. Walts, Jennifer C. Petter and Raj Bhikhu Parekh in 2015 and is headquartered in Waltham, MA. | Pharmaceuticals: Major | Founder Founder | |
Arvelle Therapeutics International GmbH
Arvelle Therapeutics International GmbH BiotechnologyHealth Technology Arvelle Therapeutics GmbH provides treatment for patients suffering form CNS disorders. The company was founded by Ilise Lombrado, Gregory Mark Weinhoff and Mark Altmeyer and is headquartered in Basel, Switzerland. | Biotechnology | Director/Board Member | |
Aleta Biotherapeutics, Inc.
Aleta Biotherapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Aleta Biotherapeutics, Inc. engages in the immuno-oncology service that focuses on transforming cellular therapeutics. It allows broad spectrum of cancer indication to be targeted including currently intractable solid tumors. The company was founded by Paul Rennert and Roy Lobb and is headquartered in Natick, MA. | Miscellaneous Commercial Services | Director/Board Member | |
Tridek-One Therapeutics SAS
Tridek-One Therapeutics SAS Miscellaneous Commercial ServicesCommercial Services Tridek-One Therapeutics SAS is a French private biotechnology company founded in 2018. The company is based in Paris, France. Tridek-One's scientific founders at INSERM conducted groundbreaking research on the role of CD31 in the modulation of the immune response, which forms the basis of the company's work. The company was founded in 2019 by Giuseppina Caligiuri, Antonino Nicoletti, and the CEO is Laurence de Schoulepnikoff. | Miscellaneous Commercial Services | Director/Board Member | |
Amphista Therapeutics Ltd.
Amphista Therapeutics Ltd. BiotechnologyHealth Technology Amphista Therapeutics Ltd. is a biopharmaceutical company based in Biocity Glasgow, UK. The British company is focused on creating first-in-class therapeutics that selectively and efficiently degrade and remove disease-causing proteins using targeted protein degradation (TPD). The company's pipeline of novel small molecules is focused on challenging diseases, including cancer. Amphista is a spin-out of Professor Alessio Ciulli's labs at the University of Dundee and is funded by leading life science investors, including Advent Life Sciences, the European Investment Fund, the Scottish Investment Bank, and Biomotiv. The CEO of the company is Nicola Thompson. | Biotechnology | Director/Board Member | |
Performance Electronics Ltd.
Performance Electronics Ltd. Electronic Production EquipmentElectronic Technology Performance Electronics Ltd. designs and manufactures embedded electronic control systems. The private company is based in Cincinnati, OH. | Electronic Production Equipment | Director/Board Member | |
Alpha Anomeric SA | Director/Board Member | ||
Pheno Therapeutics Ltd.
Pheno Therapeutics Ltd. Miscellaneous Commercial ServicesCommercial Services Pheno Therapeutics Ltd. operates as a biotechnology company. The firm develops remyelinating therapies for the unmet need for a neuroprotective therapy for multiple sclerosis. The company was founded on October 31, 2018 and is headquartered in Edinburgh, the United Kingdom. | Miscellaneous Commercial Services | Director/Board Member | |
Alpha Anomeric SAS
Alpha Anomeric SAS Pharmaceuticals: MajorHealth Technology Alpha Anomeric SAS Develops genetic medicines for severe neuromuscular diseases. The company is headquartered in Paris, France. | Pharmaceuticals: Major | Director/Board Member | |
Vico Therapeutics BV
Vico Therapeutics BV BiotechnologyHealth Technology Vico Therapeutics BV is a private biotech company based in Leiden, Netherlands that focuses on developing RNA modulating therapies for rare severe neurological disorders. The Dutch company's antisense oligonucleotide platform (AON) is directed towards different forms of spinocerebellar ataxia (SCA) and Huntington disease (HD), while its early discovery RNA editing platform is directed towards Rett syndrome. Vico Therapeutics was founded in 2019 by Luc Dochez, Josh Mandel-Brehm, Gail Mandel, and Dr. Judith van Deutekom, who have strong academic reputations and vast industry experience. Micah Mackison has been the CEO of the company since 2022. | Biotechnology | Director/Board Member Director/Board Member | |
Rappta Therapeutics Oy
Rappta Therapeutics Oy BiotechnologyHealth Technology Rappta Therapeutics Oy operates as a biopharmaceutical company. It develops anti-cancer drugs activating protein phosphatase 2A. The company was founded by Goutham Narla and Mikko Lauri Sampsa Mannerkoski on March 20, 2019 and is headquartered in Helsinki, Finland. | Biotechnology | Director/Board Member | |
Pharvaris GmbH
Pharvaris GmbH Pharmaceuticals: MajorHealth Technology Pharvaris GmbH operates as a clinical-stage company. It specializes in medicinal chemistry, drug discovery and development and hereditary angioedema. The company was founded by Berndt A. E. Modig, Jochen Knolle, Anne Lesage and Hans G. C. P. Schikan in October 2015 and is headquartered in Zug, Switzerland. | Pharmaceuticals: Major | Director/Board Member | |
EQT Life Sciences Group BV
EQT Life Sciences Group BV Investment ManagersFinance EQT Life Sciences Group BV (EQT Life Sciences) is a venture capital firm, a subsidiary of EQT AB founded in 2022 after the acquisition of LSP by EQT. The firm is headquartered in Amsterdam, the Netherlands. | Investment Managers | Private Equity Investor | |
OCULIS HOLDING AG | Pharmaceuticals: Major | Director/Board Member | |
Ventus Medical Ltd.
Ventus Medical Ltd. Medical SpecialtiesHealth Technology Ventus Medical Ltd. develops novel inhalation and NRT smoking cessation technologies. The company is based in Liverpool, UK. The British company was founded in 2014 by David Lawson, Mark Dignum. | Medical Specialties | Director/Board Member |
Statistik
International
Vereinigte Staaten | 17 |
Niederlande | 15 |
Vereinigtes Königreich | 7 |
Schweiz | 6 |
Belgien | 3 |
Sektoral
Health Technology | 30 |
Finance | 9 |
Commercial Services | 6 |
Consumer Services | 3 |
Retail Trade | 2 |
Operativ
Director/Board Member | 104 |
Director of Finance/CFO | 62 |
Corporate Officer/Principal | 22 |
Independent Dir/Board Member | 19 |
Founder | 13 |
Am stärksten vernetzte Beziehungen
Insiders | |
---|---|
Daniel Geffken | 53 |
Raj Bhikhu Parekh | 50 |
Martijn Kleijwegt | 33 |
Gregory Weaver | 22 |
Alan Walts | 17 |
Robert E. Ward | 13 |
Silvia Noiman | 10 |
Sumit Aggarwal | 9 |
Rose Villandry | 8 |
Vijay Modur | 7 |
David P. Snow | 7 |
Gregory C. Williams | 6 |
Stephen MacDonald | 4 |
- Börse
- Insiders
- Gary D Rakers
- Unternehmensverbindungen